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Yersinia pseudotuberculosis is an enteropathogenic
bacteria that disrupts the intestinal barrier and
invades its host through gut-associated lymphoid
tissue and Peyer’s patches (PP). We show that the
Y. pseudotuberculosis effector YopJ induces intes-
tinal barrier dysfunction by subverting signaling of
the innate immune receptor Nod2, a phenotype that
can be reversed by pretreating with the Nod2 ligand
muramyl-dipeptide. YopJ, but not the catalytically
inactive mutant YopJC172A, acetylates critical sites
in the activation loops of the RICK and TAK1 kinases,
which are central mediators of Nod2 signaling, and
decreases the affinity of Nod2 for RICK. Concomi-
tantly, Nod2 interacts with and activates caspase-1,
resulting in increased levels of IL-1b. Finally, IL-1b
within PP plays an essential role in inducing intestinal
barrier dysfunction. Thus, YopJ alters intestinal
permeability and promotes the dissemination of
Yersinia as well as commensal bacteria by exploiting
the mucosal inflammatory response.
INTRODUCTION
The gut epithelium efficiently protects against invasion and
systemic dissemination of the commensal flora and enteropath-
ogens. This function is mediated by epithelial cells and the gut
associated lymphoid tissue (GALT), organized in isolated
lymphoid follicles (LF) and Peyer’s patches (PP) (Jung et al.,Cell H2010). Yersinia pseudotuberculosis exploits PP formation to
invade its host, causing enteritis andmesenteric adenolymphitis.
Following their entry into PP, the bacteria induce inflammation
with infiltration of neutrophils and macrophages. In vitro,
Y. pseudotuberculosis was also shown to increase intestinal
permeability (Ragnarsson et al., 2008). However, the molecular
mechanisms linking bacterial invasion and host barrier dysfunc-
tion remain elusive.
Yersinia species harbor a virulence plasmid that encodes
a type III secretion system (T3SS), which delivers bacterial
proteins into the cytosol of targeted host cells. The translocator
proteins YopB, YopD, and LcrV form a pore in host cell
membranes, allowing the translocation of seven effector Yops
into the cytosol (Viboud and Bliska, 2005). YopE, YopH, YopT,
and YpkA target the host actin cytoskeleton, inhibit phagocy-
tosis, and allow the bacteria to remain largely extracellular.
YopK prevents the recognition of the T3SS by the host cell and
the subsequent activation of the inflammasome (Brodsky et al.,
2010). The function of YopM remains unclear.
YopJ is an acetyl-transferase that binds and acetylates serine
and threonine residues within the activation loops of several
kinases, includingMKKs and IKKb. As a result, YopJ inhibits their
phosphorylation and consequently their activation (Mittal et al.,
2006; Mukherjee et al., 2006). In vitro, YopJ mediates inhibition
of MAPKK and NF-kB pathways, leading to reduced production
of inflammatory cytokines and the promotion of cell death
(Viboud and Bliska, 2005). YopJ also causes activation of cas-
pase-1 and secretion of IL-1b (Brodsky et al., 2010; Lilo et al.,
2008). In Y. pestis, YopJ activates the NLRP3/ASC/caspase-1
inflammasome in macrophages (Zheng et al., 2011). In contrast,
the in vivo role of YopJ is less well defined. Following oral infec-
tion, YopJ promotes bacterial colonization in mice and induces
apoptosis of immune cells in lymphoid tissues (Brodsky andost & Microbe 11, 337–351, April 19, 2012 ª2012 Elsevier Inc. 337
Figure 1. Yersinia pseudotuberculosis Effector YopJ Disrupts the Intestinal Barrier
(A) Paracellular permeability of Peyer’s patches (PP) and ileal mucosa (IL) after i.g. infection with Y. pseudotuberculosiswild-type strain pIB102 (1.107 cfu). C57B6
micewere sacrified at 1, 3, 6, and 12 hr after infection. For eachmeasure, PP and IL biopsies from fivemiceweremounted in UC (see Figure S1) and the flux of 4kD
FITC-dextran was monitored during 2 hr. (n = 7 biopsies per group from at least two experiments; *p < 0.05 and **p < 0.01 versus noninfected).
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YopJ also induces interleukin-18 and gamma interferon in the
sera of mice and increases the number of neutrophils in the
spleen (Zhang and Bliska, 2010). However, how YopJ interacts
in vivo with the host innate immune response is not fully
understood.
Bacterial sensing by the host is based on the recognition of
microbe-associated molecular patterns (MAMPs) by innate
immune receptors, including toll-like receptors (TLRs) and
NACHT-leucine-rich repeats (NLRs). Among them, nucleotide
oligomerization domain 2 (NOD2), a NLR expressed intracellu-
larly in myelomonocytic cells and activated epithelial cells,
recognizes muramyl-dipeptide (MDP), a moiety of the bacterial
cell wall peptidoglycan of almost all bacteria. Following its acti-
vation by MDP, NOD2 interacts with the serine-threonine kinase
RIP-like interacting caspase-like apoptosis regulatory protein
kinase (RICK) and subsequently activates the nuclear factor-kB
(NF-kB) and MAPK pathways. NOD2 is also involved in the in-
flammasome-dependent secretion of IL-1b (Hsu et al., 2008).
In vivo, Nod2 is important for the homeostasis of PP, for intestinal
barrier function, and for the host response against Yersinia (Bar-
reau et al., 2010; Barreau et al., 2007; Meinzer et al., 2008). The
aim of this work was to explore the role of Nod2 in Yersinia-
induced epithelial barrier dysfunction.
RESULTS
YopJ Contributes to Intestinal Barrier Dysfunction
Y. pseudotuberculosis increases intestinal permeability in vitro
(Ragnarsson et al., 2008). To explore the involved bacterial viru-
lence factors, we first studied the ex vivo transepithelial flux of
4kD-Dextran FITC, a marker for paracellular permeability.
C57B6 wild-type (wt) mice were intragastrically (i.g.) inoculated
with 107 colony forming units (cfu) of the YPIII(pIB102) wt bacte-
rial strain. At 1, 3, 6 and 12 hr post-infection, micewere sacrificed
and ileal biopsies centered on PP formations were mounted in
Ussing chambers (UC) (Figure S1). The flux of 4kD-dextran
significantly increased as early as 6h (Figure 1A). In PP-free ileal
biopsies, Y. pseudotuberculosis also increased the permeability
with comparable kinetics but with lower amplitude (Figure 1A).
To investigate the role of the virulence plasmid we used genet-
ically modified derivates of the wt strain (Table S1). YPIII(pIB604)
does not express YopB and therefore cannot form the pore
necessary for the translocation of the effector Yops. YPIIIMEKAJ
(DHMEKAJ) is able to form the translocation apparatus but does
not express any of the effector Yops. In UC, pIB604 and DHME-
KAJ failed to increase paracellular permeability, demonstrating(B) Effect of Yops on the ex vivo paracellular permeability after Y. pseudotubercu
with 1.107 cfu/ml of the different bacterial strains (see Table S1). Paracellular perm
experiments; ***p < 0.001 versus noninfected; 2+p < 0.01 and +++p < 0.001 versu
(C) Effect of YopJ on the ex vivo bacterial translocation of E. ColiK12 across PP inf
UC. (n = 7 per condition from at least two experiments; *p < 0.05 and ***p < 0.00
(D) Effect of YopJ acetylation function on the ex vivo translocation of E.
Y. pseudotuberculosis 32777 (wild-type) or the catalytically inactive YopJmutant 3
noninfected; 2+p < 0.01 versus pIB102).
(E and F) In vivo role of YopJ on the paracellular and transcellular routes. Mice wer
transcellular permeabilities (F) were monitored by FITCmarkers in serum at 1, 2 an
***p < 0.001 versus noninfected; +p < 0.05 and 2+p < 0.001 versus pIB102). All re
Cell Hthat the translocation pore and one or more effector Yops are
required for barrier dysfunction (Figure 1B). Among a panel of
bacterial strains defective for single Yops, YopJ was associated
with the observed phenotype, whereas no significant differences
were observed for the other Yops (Figure 1B). Finally, the bacte-
rial strain DHMEKA, which is capable of translocating YopJ but
none of the other Yops, restored the effect of the DHMEKAJ
bacteria (Figure 1B). We thus concluded that YopJ was neces-
sary and sufficient to alter paracellular permeability ex vivo.
The same experiments were performed with a fluorescently
labeled heat-killed E. coli K12 as a marker of bacterial transloca-
tion. Comparable results were seen with respect to the fully viru-
lent pIB102 wt strain, the defective pIB604, DHMEKAJ, DYopJ
and DHMEKA strains (Figure 1C). In addition, a strain of
Y. pseudotuberculosis serogroup O:1 carrying a catalytically
inactive YopJ mutant (32777mJ) and its isogenic wt control
(32777) confirmed the importance of YopJ acetylase activity
(Figure 1D). As a whole, we concluded that YopJ also affects
bacterial translocation ex vivo.
To evaluate the in vivo role of YopJ, C57BL6 mice were i.g.
inoculated with a single dose of wt or YopJ-deficient (DYopJ)
bacteria. At days 1, 2 and 5 after infection, 4kD-dextran FITC
markers were i.g. inoculated and the marker concentrations
were measured in the serum. The same experiments were
done with 40 kDa dextran FITC, a marker of transcellular perme-
ability. For both markers, serum levels were severely increased
after infection with the fully virulent wt strain (Figures 1E and
1F). In contrast, an attenuated effect was observed with DYopJ,
confirming the role of YopJ in vivo.
YopJ Contributes to Bacterial Dissemination from the
Gut and Animal Mortality
To understand the impact of YopJ induced barrier dysfunction,
we counted the number of Yersinia colonies present in the
caecum, PP, PP-free ileum, mesenteric lymph nodes (MLN)
and spleen at days 1, 2 and 5 after i.g. inoculation of wt or DYopJ
bacteria. Similar bacterial counts were found in both groups in
the caecum at all time points, confirming that the DYopJ strain
normally colonizes the host gut lumen (Figure 2A), as previously
reported. The earliest differences occurred in PP where bacterial
colonization was transiently delayed for the DYopJ strain (Fig-
ure 2B). Outside of PP formations, ileum colonization was also
impaired at day 2 (Figure 2C). Finally, after day 2,DYopJ bacteria
were less numerous in the MLN and spleen (Figures 2D and 2E).
YopJ-induced barrier dysfunction was thus associated with
earlier colonization of the gut and higher dissemination into
deeper organs.losis infection. PP were removed from 12 mice, mounted in UC and incubated
eability was monitored during 2 hr (n = 7 for each condition from at least three
s pIB102).
ectedwith differentY. pseudotuberculosis strains (1.107 cfu/ml) andmounted in
1 versus noninfected; +++p < 0.001 versus pIB102).
Coli K12. PP were mounted in UC and incubated with 1.107 cfu/ml of
2777MJ. (n = 7 per condition from at least three experiments; **p < 0.01 versus
e i.g. inoculated (1.107 cfu) with pIB102 or DYopJ strains, and paracellular (E) or
d 5 days after infection. (n = 7mice for each condition; *p < 0.05, **p < 0.01 and
sults are expressed as means ± SEM.
ost & Microbe 11, 337–351, April 19, 2012 ª2012 Elsevier Inc. 339
Figure 2. YopJ Is Involved in PP Colonization, Bacterial Translocation, and Mouse Survival
(A–F) Role of YopJ inbacterial translocation in vivo.Mice infectedwithY. pseudotuberculosispIB102orDYopJ strains (1.107 cfu)were sacrificed at days1, 2, or 5, and
Y.pseudotuberculosiscfuwerecounted inCaecum(A),Peyer’spatches (B), Ileum(C),mesenteric lymphnodes (D), andspleenhomogenates (E). (F)Bacteriaother than
Yersinia spp.werealsomonitored in thespleen.Dataare representativeof three independent experiments (n>6micepergroup;mean±SEM; *p<0.05and **p<0.01).
(G) Survival curves after intragastrical inoculation of WT mice with pIB102 or DYopJ strains (1.53 108 cfu) (pooled data from at least two experiments, n = 20 per
group; **p < 0.001).
(H)Mouse survival after intraperitoneal inoculation of pIB102 orDYopJ strains (0.43 104 cfu) (n = 10 per group from two independent experiments; not significant).
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Figure 3. YopJ-Induced Intestinal Barrier Dysfunction Requires Nod2 Expression
(A) In vivo measure of transcellular permeability in Nod2/ mice i.g. inoculated with pIB102 or DYopJ strains (1.107 cfu). The serum concentrations of 40 kDa
FITC-dextran were monitored at days 1, 2, and 5 after infection. (n = 7 per condition from three pooled experiments; mean ± SEM; 2+p < 0.01vs. noninfected).
(B) Survival curves of Nod2/ mice i.g. inoculated with pIB102 or DYopJ (1.5.108 cfu) (pooled data from two independent experiments, n = 10 per group; not
significant).
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E. coli in vitro, we also counted the bacteria other than
Y. pseudotuberculosis. At day 2, those bacteria were transiently
found in the spleens of all wt infected mice but in only one of
seven mice infected with DYopJ (Figure 2F). Thus, it is possible
that YopJ also contributes to the translocation of commensal
bacteria from the gut flora during acute Yersiniosis.
The impact of YopJ on bacterial dissemination incited us to
explore its role on host survival. After i.g. inoculation, YopJ defi-
ciency did not significantly alter the power of the bacteria to kill
mice at the tested concentration (1.5 3 108 cfu), confirming
that YopJ has only a limited impact on global bacterial virulence
(Auerbuch and Isberg, 2007). However, the YopJ deficiency was
associated with delayed mortality (Figure 2G). This difference
was statistically significant and reproducible in multiple experi-
ments. To explore if this effect was related to gut colonization
and translocation, we also performed intraperitoneal (i.p.) infec-
tions. As previously reported (Brodsky and Medzhitov, 2008), no
survival differences were observed between the DYopJ and wt
strains (Figure 2H). Thus, the effects of YopJ on the gut barrier
likely contribute to bacterial virulence.
YopJ Interacts with the NOD2 Pathway
Because a Nod2 deficiency is associated with a delayed
mortality in mice infected with Y. pseudotuberculosis (Meinzer
et al., 2008), we explored the putative link between YopJ and
Nod2. In Nod2 knock-out mice (Nod2/), the wt and DYopJ
bacteria had a similar and limited effect on the transcellular
permeability measured in vivo by the 40 kDa dextranmarker (Fig-
ure 3A). After i.g. inoculation, Nod2/ mice also exhibited the
same delayedmortality with the two bacterial strains (Figure 3B).
The NOD2 1007frame-shift mutation is associated with
Crohn’s disease (CD) (Hugot et al., 2001). C57B6 mice carrying
a mutation homologous to the Human one (Nod22939iC), display
a survival advantageafter oral infectionwithY.pseudotuberculosis
(Meinzer et al., 2008). In this secondmousemodel, we also failed
to see differences between the wt or DYopJ strains in terms of
survival (Figure 3C). Together, these observations suggested
a resistance of the Nod2/ and Nod22939iC mice toward YopJ.
We next examined the effect of MDP on YopJ-induced intes-
tinal barrier dysfunction. PP from wt mice pretreated with i.p.
injections of MDP were mounted in UC and infected with the
wt or DYopJ strains. MDP decreased the intestinal translocation
of E. coli in PP infected with pIB102 but not in PP infected with
DYopJ (Figure 3D). In vivo, i.p. injections of MDP before i.g. inoc-
ulation of pIB102 were associated with delayed mortality (Fig-(C) Survival curves after i.g. inoculation of Nod22939iCmice with pIB102 or DYopJ
significant).
(D) Impact of MDP on ex vivo translocation of E. coli. PP from mice pretreated o
experiments, n = 7 per group; mean ± SEM; ***p < 0.001 versus noninfected; 2+p
(E) Survival curves of mice i.p. treated with or without MDP and i.g. inoculated wi
***p < 0.001).
(F) In vivo measure of the paracellular permeability in WT mice i.p.-treated with
measured at days 1, 2, and 5 after infection (pooled data from two experiments,
2+p < 0.01 versus pIB102 without MDP).
(G) Specificity of MDP treatment on ex vivo measures of paracellular permeability.
mice), ie-DAP (150 mg/mice, Nod1 agonist), Pam3CSK4 (100 mg/mice, TLR-2 ago
experiments (n = 8 per group; mean ± SEM; **p < 0.01 and ***p < 0.001 versus n
342 Cell Host & Microbe 11, 337–351, April 19, 2012 ª2012 Elsevierure 3E), decreased bacterial dissemination into the spleen at
day 5 (Figure S2A), and reduced in vivo paracellular permeability
(Figure 3F). MDP had no effect on survival after i.p. infection
(Figure S2B).
MDP was thus able to reverse the biological effects of YopJ
further supporting a connection between Nod2 and YopJ. This
effect was specific to MDP as alternative PAMPs including
ie-DAP (a NOD1 ligand), PAMC3Csk4 (a TLR2 ligand) or LPS
(a TLR4 ligand) failed to reverse the Yersinia-induced barrier
dysfunction (Figure 3G).
YopJ Reduces the Affinity of the NOD2-RICK Complex
Under MDP stimulation, NOD2 is known to recognize and acti-
vate RICK. We thus analyzed the impact of YopJ on the
NOD2-RICK complex in real time and in living cells by Biolumi-
nescence Resonnance Energy Transfer (BRET) (Figure S3A).
As expected, we observed a specific and direct interaction
between NOD2 and RICK which was favored by incubating
with MDP (Figure 4A). The effects of MDP correlated with
NOD2-induced NF-kB activity, underscoring its role on RICK-
dependent NOD2 activation (Figure S3B). The same experiments
were done in the presence of wt YopJ or its catalytically inactive
form YopJC172A. Wt YopJ decreased the affinity between NOD2
andRICK, as indicated by a two fold increase of the apparent Kd.
This effect was reversed by MDP stimulation (Figure 4B). In
contrast, the YopJC172A null mutant had no effect on NOD2-
RICK saturation profile and affinity (Figure 4B). Changes in
NF-kB activation also paralleled NOD2-RICK interaction in lucif-
erase assays (Figure S3B).
To further demonstrate the impact of YopJ on the NOD2-RICK
complex, we finally developed a Duolink assay looking for
NOD2/RICK interactions in THP1 cells, which naturally express
these molecules. The results were concordant with BRET data
with a low number of NOD2-RICK interactions after infection
by pIB102 but a high number of complexes after infection by
DYopJ or MDP pretreatment (Figure 4C). Altogether, these find-
ings indicated that YopJ inhibits the NOD2-RICK interaction.
YopJ Acetylates RICK and TAK1
Because the acetyl-transferase activity of YopJ was necessary
to increase intestinal permeability (Figure 1D), we explored if it
was able to acetylate NOD2 or RICK. Myc-tagged Nod2 or
RICK proteins were coexpressed in HEK293T cells together
with YopJ and analyzed by mass spectroscopy. We failed to
detect an acetylation of NOD2 while RICK was acetylated on
several residues (Figure 4E and Table S2). No acetylation wasstrains (1.5.108 cfu) (pooled data from three experiments, n = 10 per group; not
r not with MDP were infected with pIB102 or DYopJ (pooled data from three
< 0.01 versus pIB102).
th 1.5.108 cfu of pIB102 (pooled data from two experiments, n = 16 per group;
MDP (100 mg). Serum concentrations of the 4 kDa FITC dextran marker were
n = 6 per group; mean ± SEM; **p < 0.01 and ***p < 0.001 versus noninfected;
One day before experimentation, WTmice were i.p.-treated with MDP (100 mg/
nist), or LPS (100 mg/mice, TLR-4 agonist). Shown are pooled data from three
oninfected; 2+p < 0.01 versus pIB102). See also Figure S2.
Inc.
Figure 4. YopJ Disrupts the NOD2-RICK Complex and Acetylates RICK and TACK1
(A and B) BRET titration experiments between NOD2 and RICK in presence of MDP and/or YopJ or the catalytically inactive YopJC172A. Regression curves are
represented as the percentage of BRETmax value as a function of the fluorescence/luminescence ratio. All titration regression curves fitted with a R2 coefficient >
0.98. All curves were significantly different (p < 0.01) except the conditions with MDP stimulation (A, triangles and filled circles). Affinity between NOD2 and RICK
(apparent Kd) corresponds to the BRETmax/2 value (BRET50). Shown are representative data from three independent experiments in triplicate.
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tive YopJ mutant (YOPJC172A) (data not shown). Interestingly,
among the acetylated residues, three serines (S174, S176,
S178) are located within the activation loop of RICK and their
phosphorylation is critical for the catalytic activity of the protein
(Dorsch et al., 2006; Oppermann et al., 2009).
NOD2 has also been shown to interact with Transforming
growth factor b-activated kinase 1 (TAK1), a member of the
MAP3K family. TAK1 is an essential downstream molecule for
NOD2-RICK-mediated activation of the NF-kB and MAPK
signaling pathways (Chen et al., 2004; Windheim et al., 2007)
and our RNA silencing experiments confirmed that TAK1 is
required for MDP-mediated activation of NF-kB (Figure S3C).
YopJ has been proposed to inhibit the NF-kB pathway at the
level of TAK1 (Haase et al., 2005; Sweet et al., 2007), but it is
currently not clear whether YopJ acts directly on TAK1. We
found that YopJ also acetylates TAK1 on several threonine resi-
dues (Figure 4F and Table S2) in transfected HEK293T cells.
Acetylations were not observed when TAK1 was coexpressed
with YOPJC172A (data not shown). Here too, the acetylated thre-
onine residues (T184 and T187) were located within the activa-
tion loop of TAK1 and their phosphorylation is critical for the
catalytic activity of the protein (Singhirunnusorn et al., 2005; Yu
et al., 2008). Therefore, by acetylating these residues YopJ
may inhibit TAK1 kinase activity.
RICK or TAK1 Inhibition Results in an Intestinal Barrier
Dysfunction
To confirm that TAK1 inhibition contributes to the intestinal
barrier dysfunction, we explored the permeability of wt mice
treated with the TAK1-specific inhibitor 5Z-7-oxozeanol. In non
infected PP, 5Z-7-oxozeanol had no effect on the translocation
of E.coli, while 5Z-7-oxozeanol increased intestinal permeability
induced by DYopJ bacteria to a level similar to YopJ-expressing
bacteria (Figure 5A). Similar results were obtained for 32777MJ
bacteria lacking the catalytic site of YopJ (Figure 5A). Finally,
we explored the role of TAK1 on intestinal permeability by
studying Tak1-deleted mice. Tak1-/- mice had similar increased
intestinal permeability after infection with YopJ-positive as well
as YopJ-negative strains (Figure 5A). We thus concluded that
TAK1 inhibition is able to induce intestinal barrier dysfunction.
To explore the impact of RICK inhibition on intestinal perme-
ability, we used SB203580, a RICK inhibitor. In vivo, SB203580
did not change the 40 kDa dextran transcellular permeability
induced by wt bacteria but it fully restored the effect of the
DYopJ strain (Figure 5B). Similar results were obtained with re-
gard to E. coli translocation across PP in UC experiments (Fig-
ure 5C) using SB203580 (which also inhibits p38 MAPK) or(C) Quantification of RICK-NOD2 interactions in THP-1 cells by Duolink proximity
before infection (pooled results from three independent experiments, n = 150 THP
+++p < 0.001 versus pIB102). Representative images are shown.
(D) Mass spectrometry analyses of acetylated and alkylated peptides in the ac
aminoacid 172-179 (mascot score 35). The precursor of this RICK peptide underg
on theMS/MS spectra and labeled on the peptide sequence (blue). O-Ac stands fo
(E) Mass spectrometric analysis of an acetylated and alkylated peptide in the ac
amino acid 173-190 (mascot score 49). The precursor ofmass to charge of 1113,46
and y (blue) ions are marked on theMS/MS spectra and labeled on the peptide seq
for carbamidomethyl. See also Figure S3 and Table S2.
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suggest that RICK inhibition also plays a role in YopJ induced
intestinal barrier dysfunction.
IL-1b Production in PPs Is Correlated with Intestinal
Barrier Dysfunction
RICK and TAK1 have a well established role in NOD2 mediated
NF-kB activation. It could thus be postulated that the YopJ effect
on intestinal barrier dysfunction was related to NF-kB inhibition.
However, in contrast to the MDP-reversible effect of YopJ on
intestinal barrier dysfunction (Figure 3D), YopJ inhibition of
NF-kB activation was not reversible by MDP (Figure S3B). As
a result, we hypothesized that YopJ-induced barrier dysfunction
was mediated by an alternative molecular pathway.
In addition to NF-kB activation, NOD2 is involved in caspase-1
activation and IL-1b secretion (Hsu et al., 2008). Similarly, YopJ
induces caspase-1 activation and IL-1b secretion in mouse
macrophages (Lilo et al., 2008). Consequently, we investigated
whether IL-1b secretion correlated with intestinal barrier
dysfunction with respect to its YopJ-, Nod2-, RICK- and TAK1-
dependency and MDP-reversibility. IL-1b levels in PP, PP-free
ileum and spleen were measured after i.g. inoculation of
Nod2+/+ and Nod2/ mice with wt and DYopJ strains. IL-1b
concentrations were increased in Nod2+/+ mice infected with
pIB102 but not in Nod2+/+ mice infected with the DYopJ strain
or Nod2/ mice infected with pIB102 (Figure 5D). Comparable
but less marked observations were made on PP-free ileal biop-
sies (Figure S4A), while in spleens IL-1b secretion was not
altered by either Nod2 deficiency or YopJ deletion (Figure S4B).
Because the increased IL-1b levels observed in vivo could be
the result of a higher bacterial burden in PP, PP extracted from
Nod2+/+ and Nod2/ mice were infected ex vivo with
a controlled number of pIB102 or DYopJ bacteria. We repro-
duced the in vivo observations and also showed that MDP was
able to reverse the effect of YopJ on IL-1b production (Figure 5E).
In presence of the chemical inhibitors of RICK (SB203580 or PP2)
or TAK1 (5Z-7-oxozeanol), the DYopJ strain induced similar
levels of IL-1b as YopJ expressing bacteria (Figure 5F). Similar
results were obtained when using the strains expressing the
catalytically inactive YopJ mutant (Figure S4C). Altogether these
data showed that IL-1b production strictly paralleled intestinal
dysfunction.
IL-1b Secretion Increases the Intestinal Permeability
To confirm that IL-1b production is the key factor responsible
for inducing intestinal barrier dysfunction, PP from C57B6
mice were pretreated with Anakinra, an IL-1R antagonist,
before ex vivo infection with pIB102. Anakinra abrogated theligation assay. THP1 cells were pretreated or not with MDP (20mg/ml) for 24 hr
-1 cells per group; mean ± SEM; *p < 0.05 and ***p < 0.001 versus noninfected;
tivation loop of RICK with mass-to-charge ratio of 507.2241 z = 2 spanning
oes a double oxidized methione with neutral loss (128). The y ions are marked
r O-acetylated Threonine or Serine residue. CAM stands for carbamidomethyl.
tivation loop of TAK1 with mass-to-charge ratio of 1113,4681 (z = 2) spanning
81 (z = 2) undergoes an oxidizedMethionine with Neutral loss (64). The b (red)
uence. O-Ac stands for O-acetylated Threonine or Serine residue. CAM stands
Inc.
Figure 5. TACK1 or RICK Inhibitions Alter the Intestinal Barrier; IL-1b Levels and Intestinal Permeability Change in Parallel
(A) Impact of TACK1 inhibition on ex vivo E. Coli translocation by pretreatment with 5Z-7-Oxozeanol or gene knock-out. PP from WT or Tak1/ mice were
mounted in UC after incubationwith different Y. pseudotuberculosis pIB102,DYopJ, 32777 or 32777mJ strains (1.107 cfu/ml, pooled data from three experiments
(n = 7 PP per condition); ***p < 0.001 versus non infected; +++p < 0.001 versus DYopJ; 44p < 0.01 versus 32777mJ).
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YopJ-Induced Barrier DysfunctionpIB102-induced translocation of E. coli across PP (Figure 6A).
Yersinia induced barrier dysfunction was also studied in mice
lacking the IL-1 receptor (IL-1R/). pIB102 was no longer able
to increase thebacterial translocationofE. coli ex vivo (Figure 6A),
nor the transcellular permeability in vivo (Figure 6B). Finally,
because IL-1b secretion is usually dependent of caspase-1 acti-
vation, we used the selective caspase-1 inhibitor Z-YVAD-FMK,
which also reduced the translocation of E. coli induced by
pIB102 (Figure 6A). Together, these findings pointed out a crucial
role for IL-1b in inducing the intestinal barrier dysfunction.
YopJ Activates Caspase-1 through the Formation
of Nod2/Caspase-1 Complexes
To further explore the mechanisms involved in IL-1b pro-
duction, we monitored IL-1b secretion, caspase-1 activity
and pro-IL1b concentration in THP1 cells infected with
Y. pseudotuberculosis strains. As expected, IL-1b production
(Figure 6C) and caspase-1 activity (Figures 6D and 6E) showed
parallel changes. Noteworthy, caspase-1 expression levels
were higher in case of infection with pIB102 (Figure 6E). This
finding may be due to the inhibitory role of YopJ on IKKb (Greten
et al., 2007). Higher levels of proIL-1bwere also found after infec-
tion by pIB102 compared to theDYopJ strain butMDP had a less
marked effect (Figure 6F). Finally, RICK silencing was sufficient
to restore IL-1b secretion after infection with the DYopJ strain
(Figure 6G). As a whole, these data strongly argued for cas-
pase-1-mediated IL-1b secretion in the presence of YopJ.
To understand the role of Nod2 in the RICK/YopJ-mediated
effect on caspase-1, we looked for the impact of Nod2 silencing
on caspase-1 activity. Nod2 silencing was associated with
a defect in caspase-1 activation (Figure 7A). Nod2 has been
shown to directly interact with caspase-1 in cells overexpressing
Nod2 (Hsu et al., 2008). To limit potential biases related to over-
expression systems, we developed a duolink approach to
examine endogenous NOD2/caspase-1 interactions in wt
THP-1 cells. A two-fold increase in the visualized interactions
was observed after infection with pIB102, when compared to
basal conditions (Figure 7B). The Nod2/caspase-1 interaction
was also confirmed by co-immunoprecipitation experiments
(Figure 7C). As expected, Nod2 silencing abrogated the
observed differences (Figure 7D), further validating the speci-
ficity of the interactions revealed by the duolink method. The
number of Nod2/caspase-1 interactions was not elevated after
infection with DYopJ and/or MDP pretreatment (Figure 7A),
and RICK silencing was able to complement the DYopJ strain
(Figure 7E). Altogether, these data indicated that YopJ induced(B) In vivo measure of the transcellular permeability in mice intraperitoneally tre
dextran FITCmarker weremeasured 5 days after i.g. inoculation (1.107 cfu) with pI
***p < 0.001 versus noninfected; +p < 0.05 versus DYopJ).
(C) Impact of RICK inhibitors SB203580 or PP2 on the ex vivo bacterial transloca
strain; ***p < 0.001 versus noninfected; 2+p < 0.01 versus pIB102).
(D) In vivo IL-1b secretion after Yersinia infection. Mice were i.g.-inoculated with pI
ELISA in the mucosa (pooled data from two experiments, n = 6 per group; 2+p <
(E and F) Ex vivo IL-1b secretion after Yersinia infection. PP were removed from
32777MJ strains (1.107 cfu/ml). After 6 hr, the levels of IL-1b in the supernatant
consecutive days with MDP (100 mg/mouse/day), SB203580 (100 mg/mouse/day
pooled data from three independent experiments (n = 7 per group), **p < 0.01 versu
0.05 and 44p < 0.01 versusNod2+/+ +DYopJ; +p < 0.05 and 2+p < 0.01 versusNod
346 Cell Host & Microbe 11, 337–351, April 19, 2012 ª2012 Elseviercaspase-1 activation through the formation of Nod2-caspase-1
complexes.
DISCUSSION
The interaction between Yersinia and host cells has been asso-
ciated in vitro with increased paracellular permeability together
with transcytosis of nanoparticles (Ragnarsson et al., 2008;
Tafazoli et al., 2000). In humans, acute yersiniosis results in
increased permeability to small molecules (Lahesmaa-Rantala
et al., 1991; Serrander et al., 1986). In this study, we confirm
thatY. pseudotuberculosis alters intestinal epithelial barrier func-
tion. This effect is observed when using markers of the paracel-
lular and transcellular routes and entire bacteria, indicating a
general defect of the intestinal barrier. Because Yersinia pseudo-
tuberculosis specifically recognize M cells located on the dome
of LF, it is not a surprise to find a maximum effect within PP.
The intestinal barrier dysfunction is mainly driven by the viru-
lence factor YopJ. In agreement with previous data (Auerbuch
and Isberg, 2007; Monack et al., 1998), we confirmed that
YopJ had little effect via the i.p. route, suggesting that its main
role is related to gut invasion and dissemination from the intes-
tine. Indeed, after intestinal infection, YopJ precipitates the
timing of Y. pseudotuberculosis colonization of PP and deeper
organs and the death of infected animals. Notably, YopJ also
increases the translocation of commensal gut bacteria, which
may also contribute to Yersinia pathogenicity, including reactive
arthritis or erythema nodosum.
At least in vitro, YopJ acetylates RICK and TAK1, two direct
downstream NOD2 effectors. The key role of TAK1 in YopJ
activity has been proposed previously (Haase et al., 2005; Sweet
et al., 2007), but a direct link between the two molecules re-
mained to be established. The positions of the acetylated resi-
dues at essential autophosphorylation sites within the activation
loops of RICK and TAK1 suggested that they may have a biolog-
ical impact. This opinion is further supported by additional
models of RICK or TAK1 inhibition.
The inhibition of RICK by YopJ reduces its affinity for NOD2.
This effect is reversible by MDP pretreatment, suggesting that
it is a dynamic process. When RICK is inhibited, NOD2 is able
to form a complex with caspase-1. We thus propose that
NOD2 is in equilibrium with its two partners: RICK and cas-
pase-1. Under MDP activation, NOD2/RICK interaction is
favored, resulting in NF-kB and MKK signaling, while in case of
RICK inhibition (here by YopJ), Nod2 is free to activate cas-
pase-1, resulting in IL-1b secretion. Interestingly, this model ofated with the RICK inhibitor SB203580. Serum concentrations of the 40 kDa
B102 orDYopJ (three experiments, n = 7mice for each condition, **p < 0.01 and
tion of i.p.-pretreated mice (pooled data from three experiments, n = 7 PP per
B102 orDYopJ strains (1.107 cfu) and sacrified at day 5. IL-1bwasmeasured by
0.01 versus all the other groups).
Nod2+/+ and Nod2/ mice and incubated with pIB102, DYopJ, 32777, or
were determined by ELISA. Where noted, mice were pretreated in vivo for 2
), PP2 (25 mg/mouse/day), or 5Z-7-Oxozeanol (50 mg/mouse/day). Shown are
sNod2+/+ noninfected; 4p < 0.05 and 44p < 0.01 versusNod2+/+ +DYopJ; 4p <
2+/+ + 32777MJ. All results are expressed asmeans ± SEM. See also Figure S4.
Inc.
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ing results (Eckmann and Karin, 2005).
IL-1b secretion requires pro-IL-1b processing, which, in
macrophages and dendritic cells, mainly depends on caspase-
1 activation. The role of Nod2 in this activation is less well under-
stood, and conflicting data have been published. NALP1-depen-
dent NOD2-caspase-1 interactions have been reported after
MDP stimulation (Hsu et al., 2008). However, MDP also activates
caspase-1 through NALP3 activation (Martinon et al., 2004) or
independently of NOD2 (Marina-Garcı´a et al., 2008). RICK also
interacts with caspase-1 (Thome et al., 1998), but its contribution
to MDP-enhanced caspase-1 activation seems limited (Hsu
et al., 2008). Finally, the NF-kB and caspase-1 pathways are
not independently regulated, and NF-kB inhibition has been
associated with inflammasome activation (Greten et al., 2007).
We confirm here that endogenous NOD2 interacts with cas-
pase-1 in THP1 cells, but additional studies are still required to
further clarify the NOD2 interactome.
IL-1b is one of the key mediators of inflammation, the body’s
response to microbial invasion and tissue injury. Although it
generally helps to control and to clear the infection, it can also
contribute to an uncontrolled inflammation (Siegmund et al.,
2001). In the intestine, IL-1b levels strictly paralleled epithelial
barrier dysfunction, perhaps through the activation of myosin
light-chain kinase (Al-Sadi et al., 2008).
NOD2 genetic variants have been associated with suscepti-
bility to Crohn’s Disease (CD), an inflammatory bowel condition
(Hugot et al., 2001). Several genes associated to CD, including
NOD2, ATG16L1, and NLRP3, are directly linked to the regula-
tion of IL-1b secretion (Saitoh et al., 2008; Villani et al., 2009). A
link between Yersinia and the onset of CD has been suggested
by numerous case reports, as well as an increased occurrence
of CD in people with documented yersiniosis (Saebo et al.,
2005), and an increased cellular immune reactivity against
Yersinia in CD patients (Ibbotson et al., 1992). Furthermore,
Yersinia species have been detected using PCR by two indepen-
dent groups in 63% (13/19) and 31% (17/54) of patients with CD
(Kallinowski et al., 1998; Lamps et al., 2003). The present work
further questions the relationship between enteropathogenic
Yersinia and CD. CD-associated NOD2 mutations are frequent
in Caucasians but rare in Asians and Africans, and recent natural
selection has been proposed to explain this difference
(Nakagome et al., 2012). The present data thus also question
the putative relationship between Nod2 and plague.
Enteropathogens, including Yersinia species, have developed
complex structures to subvert the host innate immune response.Figure 6. IL-1b Is Required for the YopJ-Induced PP Dysfunction; Yop
(A) Impact of inhibition of the IL-1b pathway on intestinal ex vivo translocation of E
300 mg/mouse) or with a Caspase-1 inhibitor (Z-YVAD-FMK, 100 mg/mouse/day) f
***p < 0.001 versus Nod2+/+ noninfected; +++p < 0.001 versus pIB102; +p < 0.05
(B) In vivo measure of the transcellular permeability in IL-1R/mice i.g.-inoculate
5 days after infection by the 40 kDa dextran FITCmarker (pooled data from three e
(C–F) YopJ is required for IL-1b secretion in THP1 cells. THP-1 were infected with
IL-1bweremeasured in the supernatant by ELISA. (C) Caspase-1 activity by FLICA
ELISA methods (F). Where noted, THP-1 cells were pretreated for 24 hr before
independent experiments (n = 12 per group); **p < 0.01 and ***p < 0.001 versus
(G) IL-1b levels in the supernatant of THP1 infected cells (measured by ELISA
experiments in triplicate; *p < 0.05, **p < 0.01, and ***p < 0.001 versus nontarge
348 Cell Host & Microbe 11, 337–351, April 19, 2012 ª2012 ElsevierHowever, we show here that at the early phases of the infection,
the major in vivo effect of YopJ is not related to subversion of the
host immune response but to the exploitation of the host’s
normal inflammatory reaction. The idea that the host response it-
self may sometimes be advantageous for the bacteria is not new
but well-documented examples of such situations are rare.
Salmonella typhimurium exploits inflammation to compete with
the intestinal microbiota (Stecher et al., 2007). Recently, its
effector SopE has been shown to induce caspase-1 activation
and IL-1b release by stromal cells to initiate gut inflammation
(Mu¨ller et al., 2009). Here we show that Y. pseudotuberculosis
YopJ also elicits IL-1b production in the gut to disrupt the intes-
tinal barrier and to increase its virulence.
EXPERIMENTAL PROCEDURES
For more detailed information, see also Supplemental Experimental
Procedures.
Animals
C57BL/6, wild-type, Nod2/ (Barreau et al., 2007), Tak1/ (Kim et al., 2009),
and IL-1R/ (Labow et al., 1997)micewere housed and generated in the same
pathogen-free animal facility with free access to food and water. Housing and
experiments adhered to institutional animal healthcare guidelines and were
approved by the institutional committee for animal use. Where indicated,
animals were i.p.-treated with MDP (100 mg daily) or SB203580 (100 mg daily).
Bacterial Strains
See Table S1.
In Vivo Experiments
For survival curves, mice were i.g.-inoculated with 1.5 3 108 cfu or i.p. with
0.4 3 104 cfu. Bacterial counts in organs and in vivo permeability assays
were performed as describes elsewhere (Meinzer et al., 2008). Bacteria other
than Yersinia were identified by the appearance of colonies and by comparing
the number of cfu with andwithout antibiotic selection, taking advantage of the
resistance of the Yersinia strains to kanamycin. For in vivo measures of perme-
ability, mice were gavaged with nonmetabolizable FITC-labeled dextran 4 kDa
or 40 kDa (15 mg/100 ml, Sigma) 6 hr prior to sacrifice. FITC-dextran concen-
trations were measured in the serum by a fluorometer.
Ex Vivo Experiments
UC experiments were performed as described elsewhere (Barreau et al.,
2010). Bacteria were diluted in Ringer solution to 1.5 3 107 cfu/ml, incubated
at 37C for 2 hr before being placed in the mucosal compartment of UC.
Permeability was assessed 2 hr later by measuring mucosal-to-serosal flux
of 4 kDa FITC dextran (Sigma, France). Bacterial translocation was studied
using chemically killed fluorescein-conjugated Escherichia coli K-12 (1.5 3
107/ml) (Molecular Probes, Netherlands). Where indicated, 10 mg/ml MDP,
SB203580 (10 mg/ml), anakinra (50 mg/ml), Z-YVAD-FMK (20 mg/ml), or the
same volume of vehicle were added to the mucosal side of UC.J Increases IL-1b Secretion
Coli. WT mice were pretreated i.p. with Anakinra (an IL-1 receptor antagonist,
or 2 consecutive days (pooled data from two experiments, n = 7 PP per group;
versus DMSO + pIB102).
d with pIB102 (1.107 cfu). The transcellular permeability wasmonitored at 2 and
xperiments, n = 7 mice per group; **p < 0.01 and versus noninfected WTmice).
Y. pseudotuberculosis strains pIB102 or DyopJ (moi 10). After 2 hr, the levels of
assays (D), Caspase-1 activation bywestern blot (E), and pro-IL-1b by specific
experimentation with MDP (20 mg/ml). Shown are pooled results from three
noninfected; +p < 0.05, 2+p < 0.01 and 2+p < 0.001 versus pIB102.
) are restored by RICK silencing in the absence of YopJ (three independent
ted [NT] control siRNA). All results are expressed as means ± SEM.
Inc.
Figure 7. YopJ Increases NOD2-Caspase-1 Interactions while Decreasing Nod2-RICK Interactions
(A) Caspase 1 activity in THP-1 cells treated with NOD2 or nontargeted (NT) siRNA by FLICA assay (pooled data from three experiments, **p < 0.01 versus siNT;
2+p < 0.01 versus siNT+pIB102).
(B) Quantification of NOD2-Caspase-1 interactions in THP-1 cells by Duolink assay after infection by Y. pseudotuberculosis pIB102 or DYopJ. THP1 cells were
pretreated or not with MDP (20 mg/ml, pooled results from three experiments, n = 150 THP-1 cells per group; ***p < 0.001 versus noninfected; +++p < 0.001 versus
pIB102). Representative images are shown.
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BRET titration experiments were performed by fixing the amount of the donor
RICK protein (fused to Renilla luciferase) and by increasing the amount of the
NOD2 acceptor protein fused to enhanced yellow fluorescent protein (eyfp)
coexpressed by transient transfection in HEK293 cells (see Supplemental
Experimental Procedures).
Duolink Proximity Ligation Assay
Interactions were detected by the Duolink proximity ligation assay kit (DPLA
probe anti-rabbit, DPLA probe anti-mouse; detection kit, see Supplemental
Experimental Procedures).
Mass Spectrometry Analysis of Acetylated Proteins
Myc-tagged proteins (NOD2, TAK1, or RICK) were coexpressed in HEK293T
cells together with GFPYOPJ, MycYOPJ, or MycYOPJC172A. Immunoprecip-
itated MycTAK1 or MycRICK bands were excised, prepared, and analyzed by
mass spectroscopy, as described in the Supplemental Experimental
Procedures.
Caspase-1
IL-1b, pro-IL-1b, and caspase-1 activity were determined by commercial
ELISA (BD Biosciences, France, and R&D Systems) and caspase-1 activity
(Immunochemistry Technologies, Bloomington, MN) kits. Western blots were
performed using antibodies against the cleaved caspase-1 (Temecula, CA).
Small Interfering RNAs
Small interfering RNAs (siRNAs) targetingNOD2, RICK, or TAK1 (Stealth Select
RNAi) and nontargeted (NT) control siRNA (Stealth RNAi Negative Universal
Control) were purchased from Invitrogen. THP-1 cells were transfected 48 hr
before experiments with 3.5 ml lipofectamine RNAiMax (Invitrogen, France)
with 30 pmol stealth siRNA. The efficiency of RNA silencing was monitored
by RT-PCR analyses.
Statistical Analysis
Multigroup comparisons were performed using a one-way ANOVA assuming
the Gaussian distribution (Tukey’s multiple comparison test). Two group
comparisons were performed using an unpaired t test assuming the Gaussian
distribution. The Gaussian distribution was tested by Kolmogorov-Smirnov
test. Survival was analyzed using Kaplan-Meier curves, and comparisons
were performed using the log-rank test. Wilcoxon test was used to compare
the Nod2-RICK affinity. A value of p < 0.05 was considered as statistically
significant. All p values were two sided.
SUPPLEMENTAL INFORMATION
Supplemental Information includes four figures, two tables, and Supplemental
Experimental Procedures and can be found with this article online at doi:10.
1016/j.chom.2012.02.009.
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